

# Giovanni Grignani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/246539/publications.pdf>

Version: 2024-02-01

151  
papers

9,135  
citations

50244

46  
h-index

46771

89  
g-index

155  
all docs

155  
docs citations

155  
times ranked

8364  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>CINSARC</scp> in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <scp>ISG&#x2013;STS</scp> 1001 study. <i>Cancer Medicine</i> , 2023, 12, 1350-1357.	1.3	7
2	Gastrointestinal stromal tumours: ESMO&#x2013;EURACAN&#x2013;GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33.	0.6	213
3	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator&#x2013;based risk stratification analysis of the ISG&#x2013;STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
4	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
5	Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case&#x2013;series analysis from the Italian Rare Cancers Network. <i>Cancer</i> , 2022, 128, 1439-1448.	2.0	5
6	Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 603-610.	1.1	4
7	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
8	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. , 2022, 10, e004419.		8
9	Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. , 2022, 10, e004742.		3
10	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	0.7	13
11	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi&#x2013;institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	2.0	30
12	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70.	1.8	5
13	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , 2021, 13, 1053.	1.7	15
14	Systemic therapies in advanced epithelioid haemangiioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
15	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	0.7	14
16	Post-Transplant Cyclophosphamide and Tacrolimus&#x2013;Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1173.	1.0	10
17	Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	0.7	19
18	Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. <i>European Radiology</i> , 2021, 31, 8554-8564.	2.3	20

#	ARTICLE	IF	CITATIONS
19	Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021, 11, 672021.	1.3	4
20	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65
21	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. <i>Cancers</i> , 2021, 13, 2789.	1.7	1
22	Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. <i>Cancers</i> , 2021, 13, 3046.	1.7	5
23	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	0.6	381
24	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , 2021, 149, 1926-1934.	2.3	8
25	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	1.1	10
26	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. <i>ESMO Open</i> , 2021, 6, 100222.	2.0	10
27	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STES 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	1.9	2
28	Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536.	0.6	150
29	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	0.7	26
30	Primary mesenteric sarcomas: Collaborative experience from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Journal of Surgical Oncology</i> , 2021, 123, 1057-1066.	0.8	3
31	EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewingâ€™s Sarcoma and Chondrosarcoma. <i>Cells</i> , 2021, 10, 2893.	1.8	7
32	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461.	1.3	4
33	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomasâ€”A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	1.7	0
34	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
35	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020, 5, e000787.	2.0	22
36	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85

#	ARTICLE	IF	CITATIONS
37	High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series. <i>Cells</i> , 2020, 9, 2389.	1.8	22
38	Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US). <i>Tj ETQq0 0.0 rgBT / Overlock 10</i>	0.0	0
39	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. <i>Cancer</i> , 2020, 126, 4917-4925.	2.0	21
40	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , 2020, 26, 6321-6334.	3.2	24
41	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
42	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
43	Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1905-1916.	2.0	6
44	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR $\alpha$ /SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	1.3	16
45	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. <i>Cancers</i> , 2020, 12, 1519.	1.7	15
46	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
47	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
48	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. <i>JAMA Oncology</i> , 2020, 6, 535.	3.4	33
49	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466.	5.1	51
50	Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. <i>Future Oncology</i> , 2020, 16, 15-19.	1.1	2
51	Validation process of Toronto Extremity Salvage Score in Italian: A quality of life measure for patients with extremity bone and soft tissue tumors. <i>Journal of Surgical Oncology</i> , 2020, 121, 630-637.	0.8	9
52	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489.	1.3	38
53	Endoscopic submucosal dissection for chronically bleeding gastric metastasis from undifferentiated liposarcoma. <i>Digestive and Liver Disease</i> , 2020, 52, 588.	0.4	0
54	The sacral chordoma margin. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1415-1422.	0.5	29

#	ARTICLE	IF	CITATIONS
55	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study.. Journal of Clinical Oncology, 2020, 38, 10517-10517.	0.8	2
56	IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.. Journal of Clinical Oncology, 2020, 38, 11522-11522.	0.8	14
57	Eribulin-based treatment in patients affected by sarcomas: a case series. Future Oncology, 2020, 16, 1-3.	1.1	3
58	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1252-1262.	5.1	57
59	Preventing Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380, 2180-2181.	13.9	5
60	Gain of FGF4 is a frequent event in KIT/PDGFR $\alpha$ /SDH/RAS $\Delta$ WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642.	1.5	22
61	Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes. Cancer Epidemiology, 2019, 59, 258-264.	0.8	18
62	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. Clinical Cancer Research, 2019, 25, 2664-2671.	3.2	80
63	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 134-144.	5.1	97
64	Immunological and Genetic Biomarkers of Sarcomas. , 2019, , 591-608.		0
65	NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.. Journal of Clinical Oncology, 2019, 37, 388-388.	0.8	18
66	Medical Therapy in Retroperitoneal Sarcomas. Updates in Surgery Series, 2019, , 133-141.	0.0	0
67	High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. European Journal of Cancer, 2018, 93, 28-36.	1.3	49
68	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. JAMA Oncology, 2018, 4, e180219.	3.4	63
69	Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. European Journal of Surgical Oncology, 2018, 44, 810-815.	0.5	28
70	CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. OncoImmunology, 2018, 7, e1423167.	2.1	38
71	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori, 2018, 104, 30-36.	0.6	84
72	Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Scientific Reports, 2018, 8, 4177.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. <i>Acta Oncologica</i> , 2018, 57, 958-964.	0.8	41
74	Bone sarcomas: ESMO/PaedCan/EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
75	Next generation immune-checkpoints for cancer therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1581-S1601.	0.6	50
76	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , The, 2018, 19, 1360-1371.	5.1	61
77	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	1.4	27
78	Gastrointestinal stromal tumours: ESMO/EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
79	Soft tissue and visceral sarcomas: ESMO/EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
80	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	2.9	15
81	Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. <i>Oncotarget</i> , 2018, 7, e1465161.	2.1	20
82	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	1.5	53
83	Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. <i>European Journal of Cancer</i> , 2017, 74, 9-16.	1.3	67
84	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2017, 18, 812-822.	5.1	370
85	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2017, 78, 122-132.	1.3	28
86	Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26650.	0.8	1
87	Post-Transplant Cyclophosphamide and Tacrolimus/Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 459-466.	2.0	50
88	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017, 117, 1278-1285.	2.9	33
89	Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. <i>Acta Oncologica</i> , 2017, 56, 1769-1775.	0.8	29
90	Olaratumab: PDGFR- $\alpha$ inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	2.0	16

#	ARTICLE	IF	CITATIONS
91	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1089-1103.	5.1	214
92	Alpha-fetoprotein elevation in NUT midline carcinoma: a case report. <i>BMC Cancer</i> , 2017, 17, 266.	1.1	13
93	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. <i>Molecular Cancer</i> , 2017, 16, 86.	7.9	49
94	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncologica</i> , 2017, 56, 88-92.	0.8	146
95	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2277-2288.	3.2	34
96	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	1.4	20
97	Analytic and Dynamic Secretary Profile of Patient-Derived Cytokine-Induced Killer Cells. <i>Molecular Medicine</i> , 2017, 23, 235-246.	1.9	9
98	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	0.8	126
99	Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. <i>Sarcoma</i> , 2016, 2016, 1-7.	0.7	11
100	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	0.6	90
101	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. <i>BMC Cancer</i> , 2016, 16, 793.	1.1	8
102	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. <i>Journal of Translational Medicine</i> , 2016, 14, 119.	1.8	18
103	Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. <i>BMC Cancer</i> , 2016, 16, 280.	1.1	71
104	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	6.3	610
105	Trabectedin clinical cases: use according to indication in diverse clinical scenarios. <i>Future Oncology</i> , 2015, 11, 15-24.	1.1	10
106	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2015, 16, 98-107.	5.1	270
107	Adoptive immunotherapy against sarcomas. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 517-528.	1.4	11
108	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. <i>BMC Cancer</i> , 2015, 15, 374.	1.1	24

#	ARTICLE	IF	CITATIONS
109	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502.	0.8	22
110	Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. OncoImmunology, 2014, 3, e28269.	2.1	3
111	Anticoagulation for Central Venous Catheters in Patients with Cancer. New England Journal of Medicine, 2014, 371, 1362-1363.	13.9	23
112	Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Annals of Oncology, 2014, 25, 578-583.	0.6	149
113	Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. Cancer Research, 2014, 74, 119-129.	0.4	67
114	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. European Journal of Cancer, 2014, 50, 3021-3028.	1.3	50
115	Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. BMC Research Notes, 2014, 7, 529.	0.6	24
116	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. European Journal of Cancer, 2014, 50, 784-792.	1.3	80
117	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clinical Cancer Research, 2013, 19, 2117-2131.	3.2	96
118	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Annals of Oncology, 2013, 24, 817-823.	0.6	69
119	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. Clinical Cancer Research, 2013, 19, 4347-4358.	3.2	81
120	Phase II Study of Imatinib in Advanced Chordoma. Journal of Clinical Oncology, 2012, 30, 914-920.	0.8	230
121	Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature. Oncology Research, 2012, 20, 483-490.	0.6	5
122	Gingival metastasis of a radiotherapy-induced breast angiosarcoma. Anti-Cancer Drugs, 2012, 23, 1112-1117.	0.7	6
123	Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. Journal of Immunotherapy, 2012, 35, 579-586.	1.2	21
124	Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Annals of Oncology, 2012, 23, 2970-2976.	0.6	80
125	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. Mechanisms of Ageing and Development, 2012, 133, 479-488.	2.2	9
126	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of Oncology, 2012, 23, 508-516.	0.6	296



#	ARTICLE	IF	CITATIONS
127	153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , 2012, 23, 1899-1905.	0.6	25
128	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	2.0	85
129	In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. <i>European Radiology</i> , 2012, 22, 1131-1139.	2.3	14
130	Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 139-145.	0.9	47
131	Gastrointestinal Stromal Tumors. , 2012, , 41-60.		1
132	Painful Pathologic Fracture of the Humerus: Percutaneous Osteoplasty With Bone Marrow Nails Under Hybrid Computed Tomography and Fluoroscopic Guidance. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 1031-1034.	0.2	13
133	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-1 or -2. <i>Cancer</i> , 2011, 117, 826-831.	2.0	42
134	Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?. <i>Journal of Clinical Oncology</i> , 2011, 29, e691-e693.	0.8	38
135	Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. <i>Cancer</i> , 2009, 115, 2980-2987.	2.0	50
136	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009, 8, 118.	7.9	159
137	An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 640-641.	0.6	21
138	Treatment of Extraspinal Painful Bone Metastases with Percutaneous Cementoplasty: A Prospective Study of 50 Patients. <i>CardioVascular and Interventional Radiology</i> , 2008, 31, 1165-1173.	0.9	93
139	Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. <i>European Journal of Cancer</i> , 2007, 43, 885-890.	1.3	7
140	Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. <i>Blood</i> , 2006, 107, 3795-3803.	0.6	46
141	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , 2006, 17, 1479-1488.	0.6	39
142	Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3871-3872.	0.8	30
143	Allogeneic Hemopoietic Stem Cell Transplantation in Solid Tumors. <i>Transplantation Proceedings</i> , 2005, 37, 2664-2666.	0.3	8
144	Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. <i>Clinical Cancer Research</i> , 2005, 11, 490-7.	3.2	83

#	ARTICLE	IF	CITATIONS
145	Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). <i>Journal of Clinical Oncology</i> , 2004, 22, 9021-9021.	0.8	1
146	A prognostic index for multiple myeloma. <i>British Journal of Cancer</i> , 1996, 73, 1101-1107.	2.9	64
147	MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.. <i>Journal of Clinical Oncology</i> , 1993, 11, 712-719.	0.8	22
148	Progressive necrotic myelopathy as a paraneoplastic syndrome: report of a case and some pathogenetic considerations. <i>Journal of Internal Medicine</i> , 1992, 231, 81-85.	2.7	8
149	A plea to overcome the concept of "staging" and related inadequacy in multiple myeloma. <i>European Journal of Haematology</i> , 1991, 46, 177-181.	1.1	7
150	Night sweats in Hodgkin's disease A manifestation of preceding minor febrile pulses. <i>Cancer</i> , 1990, 65, 2074-2077.	2.0	7
151	The role of surgery in the multimodal treatment of primary gastric non-Hodgkin's lymphomas a report of 76 cases and review of the literature. <i>Cancer</i> , 1990, 65, 2528-2536.	2.0	120